Experienced in Vasculitis

Dr. Kalpita M. Hatti

Rheumatology
Rheumatology Partners Of Houston, PLLC
129 Vision Park Blvd, Suite 206, 
Shenandoah, TX 
Accepting New Patients
Offers Telehealth
Experienced in Vasculitis
Rheumatology Partners Of Houston, PLLC
129 Vision Park Blvd, Suite 206, 
Shenandoah, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kalpita Hatti is a Rheumatologist in Shenandoah, Texas. Dr. Hatti is rated as an Experienced provider by MediFind in the treatment of Vasculitis. Her top areas of expertise are Rheumatoid Arthritis (RA), Necrotizing Vasculitis, Axial Spondyloarthritis (AxSpA), and Granulomatosis with Polyangiitis. Dr. Hatti is currently accepting new patients.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

RHEUMATOLOGY PARTNERS OF HOUSTON, PLLC
129 Vision Park Blvd, Suite 206, Shenandoah, TX 77384

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

1 Total Publications

Central nervous system involvement in relapsing polychondritis.
Central nervous system involvement in relapsing polychondritis.
Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
Published: October 03, 2014
Similar Doctors
Distinguished in Vasculitis
Dr. Amber R. Khan
Rheumatology
Distinguished in Vasculitis
Dr. Amber R. Khan
Rheumatology
2222 Greenhouse Rd, Suite 1300, 
Houston, TX 
 (30.9 miles away)
281-851-7088
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Amber Khan is a Rheumatologist in Houston, Texas. Dr. Khan is rated as a Distinguished provider by MediFind in the treatment of Vasculitis. Her top areas of expertise are Ankylosing Spondylitis, Axial Spondyloarthritis (AxSpA), Rheumatoid Pneumoconiosis, and Rheumatoid Lung Disease. Dr. Khan is currently accepting new patients.

Advanced in Vasculitis
Dr. Tamar F. Brionez
Rheumatology
Advanced in Vasculitis
Dr. Tamar F. Brionez
Rheumatology
10857 Kuykendahl Rd, Suite 160, 
The Woodlands, TX 
 (4.6 miles away)
281-766-7886
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Tamar Brionez is a Rheumatologist in The Woodlands, Texas. Dr. Brionez is rated as an Advanced provider by MediFind in the treatment of Vasculitis. Her top areas of expertise are Rheumatoid Arthritis (RA), Ankylosing Spondylitis, Rheumatoid Lung Disease, and Rheumatoid Pneumoconiosis. Dr. Brionez is currently accepting new patients.

Advanced in Vasculitis
Dr. Holly J. Jones
Rheumatology
Advanced in Vasculitis
Dr. Holly J. Jones
Rheumatology

Ortholonestar PLLC

7401 Main St, 
Houston, TX 
 (34.0 miles away)
713-799-2300
Languages Spoken:
English, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Holly Jones is a Rheumatologist in Houston, Texas. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of Vasculitis. Her top areas of expertise are Rheumatoid Arthritis (RA), Rheumatoid Pneumoconiosis, Rheumatoid Lung Disease, and Ankylosing Spondylitis. Dr. Jones is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hatti's expertise for a condition
ConditionClose
      View All 11 Advanced Conditions
      View All 25 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile